key: cord-0813987-buuej86h authors: Martinent, Rémi; Tawffik, Salman; López-Andarias, Javier; Moreau, Dimitri; Laurent, Quentin; Matile, Stefan title: Dithiolane quartets: thiol-mediated uptake enables cytosolic delivery in deep tissue date: 2021-10-06 journal: Chemical science DOI: 10.1039/d1sc04828g sha: 42c2cbdd3c92e6cca3433b931bca321764992f18 doc_id: 813987 cord_uid: buuej86h The cytosolic delivery of various substrates in 3D multicellular spheroids by thiol-mediated uptake is reported. This is important because most orthodox systems, including polycationic cell-penetrating peptides, fail to deliver efficiently into deep tissue. The grand principles of supramolecular chemistry, that is the pH dependence of dynamic covalent disulfide exchange with known thiols on the transferrin receptor, are proposed to account for transcytosis into deep tissue, while the known but elusive exchange cascades along the same or other partners assure cytosolic delivery in kinetic competition. For quantitative detection in the cytosol, the 2D chloroalkane penetration assay (CAPA) is translated to 3D deep tissue. The targeted delivery of quantum dots, otherwise already troublesome in 2D culture, and the controlled release of mechanophores are realized to exemplify the power of thiol-mediated uptake into spheroids. As transporters, dithiolane quartets on streptavidin templates are introduced as modular motifs. Built from two amino acids only, the varied stereochemistry and peptide sequence are shown to cover maximal functional space with minimal structural change, i.e., constitutional isomers. Reviving a classic in peptide chemistry, this templated assembly of β quartets promises to expand streptavidin biotechnology in new directions, while the discovery of general cytosolic delivery in deep tissue as an intrinsic advantage further enhances the significance and usefulness of thiol-mediated uptake. As in ref. S1. Briefly, reagents for synthesis and commercially available final compounds were purchased from Sigma-Aldrich, Brunschwig, Alfa Aesar, Merck, TCI, Acros, Iris Biotech, and Click Chemistry Tools. Wild-type streptavidin was a generous gift from Prof. 96-well sterile μ-Plates from Thermo Fischer Scientific. Fluorescence cellular imaging was performed using an IXM-C automated microscope from ImageXpress equipped with a Lumencor Aura III with 5 independently selectable solid-state light sources, bandpass filters and 5 objectives (4x to 60x). Sample preparation and washing on 96-well plates was performed using a Plate washer Biotek EL406® for the 2D cell cultures and with a Biotek MultiFlo TM FX for the spheroids. Fluorescence lifetime imaging microscopy (FLIM) was performed on a Leica SP8 DIVE FALCON microscope equipped with a white light laser (470nm -670nm) and HyD detectors. Images were acquired at 20 MHz, using a 20X water immersion objective and maintaining the temperature of the chamber at 37 °C. Average lifetimes (τav) were calculated from a biexponential fit of the signal coming from the whole image. IR spectra were recorded on a Perkin Elmer Spectrum One FT-IR spectrometer (ATR, Golden Gate) and are reported as wavenumbers ν in cm -1 with band intensities indicated as s (strong), m (medium), w (weak). 1 H and 13 C spectra were recorded on a Bruker 500 MHz spectrometer and are reported as chemical shifts (δ) in ppm relative to TMS (δ = 0). Spin multiplicities are reported as a singlet (s), doublet (d), triplet (t) and quartet (q) with coupling constants (J) given in Hz, or multiplet S7 dissolved in a minimal volume of CH2Cl2 and precipitated in pentane (x3). Crude was used in the next coupling reaction without further purification. Scheme S1 ( (CH2), 30.6 (CH2), 30.5 (CH2), 30.5 (CH2), 29.6 (CH2), 29.5 (CH2), 28.9 (3xCH3), 28.9 (6xCH3), 28.6 (3xCH3), 28.5 (3xCH3), 28.5 (3xCH3), 27.8 (CH2), 27.7 (CH2), 27.4 (CH2), 26.9 (CH2), 26.7 (CH2), 26.5 (CH2), 24.8 (2xCH2), 24.6 (CH2). Compound 52. A solution of 51 (349 mg, 182 µmol) in TFA/H2O/TIPS 95/2.5/2.5 (5 mL) was stirred at rt for 30 min. Solvent was removed in vacuo, crude was dissolved in small amount of MeOH and was precipitated in Et2O (x3) to yield 52 as a colorless TFA salt (321 mg, 98%). Crude was used in the next reaction without further purification. S13 Compound 5. To a solution of 52 (40 mg, 22 µmol) in DMF (800 µL), 37 (22 mg, 89 µmol) and DIPEA (31 µL, 178 µmol) were added and reaction mixture was stirred at rt for 1 h. Crude reaction mixture was purified by RP flash chromatography (Biotage® SNAP Ultra 12 g C18, 12 mL/min, linear gradient 20 -50% CH3CN in H2O with 0.1% TFA) to yield 5 as a colorless solid (13 mg, 32%). 1 H NMR (500 MHz, DMSO-d6/D2O 60/1): 7.82 (s, 1H), 4.37 (t, 3 JH-H = 6. 2 Hz, 2H) CuSO4·5H2O, Na-ascorbate, TBTA, THF/H2O, rt, 1 h, 86%; (m) TFA/TIPS/H2O 95/2.5/2.5, rt, 30 min, 91%; (n) 37, DIPEA, DMF, rt, 1 h, 17%. Compound 53 was prepared following a reported procedure described in ref. S8. Compound 54. To a solution of 53 (2.11 g, 7.44 mmol) in dry DMF (10 mL), was added a 30 seconds-premixed solution of HATU (3.80 g, 8.92 mmol) , Fmoc-D-Glu(OtBu)-OH (3.40 g, 8.92 mmol) and DIPEA (1.56 mL, 8.92 mmol) in dry DMF (10 mL). Reaction mixture was stirred at rt for 30 min. Reaction mixture was diluted with EtOAc and washed with NaHCO3 sat. aq. solution (x3), 10% citric acid solution (x3), water (x1), 5% LiCl solution (x2) and brine. Organic phase was then dried with Na2SO4, filtered and concentrated. Crude was dissolved in a minimal amount of CH2Cl2 and precipitated in pentane (x3). Crude was then purified by flash column chromatography (BGB® Scorpius 80 g SiO2 col., 40 mL/min, linear gradient 0 -8% MeOH in CH2Cl2) to yield 54 as a colorless solid (4.39 g, 85%). Rf (CH2Cl2 + 10% MeOH): 0.6; Compound 55 was prepared following the general procedure of Fmoc deprotection, starting from 54 (4.0 g, 5.2 mmol) in 15 mL of 2 M dimethylamine in THF, yielding 55 as a colorless solid (2.27 g, 83%) . Compound 56. To a solution of 55 (1.86 g, 3.97 mmol) in dry DMF (10 mL), was added a 30 seconds-premixed solution of HATU (1.80 g, 4.76 mmol), Fmoc-Lys(Boc)-OH (2.20 g, 4.76 mmol) and DIPEA (809 µL, 4.76 mmol) in dry DMF (10 mL). Reaction mixture was stirred at rt for 30 min. Reaction mixture was diluted with EtOAc and washed with NaHCO3 sat. aq. solution (x3), 10% citric acid solution (x3), water (x1), 5% LiCl solution (x2) and brine. Organic phase was then dried with Na2SO4, filtered and concentrated. Crude was dissolved in a minimal amount of CH2Cl2 and precipitated in pentane (x3). Crude was then purified by flash column chromatography (BGB® Scorpius 80 g SiO2 col., 40 mL/min, linear gradient 0 -8% MeOH in CH2Cl2) to yield 56 as a colorless solid (3.27 g, 90%) . Rf (CH2Cl2 + 10% MeOH): 0.5; 1.41 (s, 9H); 13 C NMR (101 MHz, CD3OD): 175.5 (C), 173.9 (C), 173.7 (C), 173.6 (C), 158.6 (2xC), 158.4 (C), 145.2 (C), 145.2 (C), 142.6 (C), 142.6 (C), 128.8 (CH), 128.8 (CH), 128.3 (CH), 128.2 (CH), 126.3 (CH), 126.2 (CH), 121.0 (CH), 120.9 (CH), 81.9 (C), 80.5 (C), 79.9 (C), 79.9 (C), 72.3 (CH), 68.1 (CH2), 57.0 (CH), 54.7 (CH), 54.1 (CH), 48.4 (CH), 41.1 (CH2), S17 41.1 (CH2), 32.7 (CH2), 32.4 (CH2), 32.3 (CH2), 30.6 (CH2), 30.4 (CH2), 29.5 (CH2), 28.8 (6xCH3), 28.4 (3xCH3), 27.7 (CH2), 24.2 (CH2), 24.1 (CH2). Compound 57 was prepared following the general procedure of Fmoc deprotection, starting from 56 (3.2 g, 3.5 mmol) in 20 mL of 2 M dimethylamine in THF, yielding 57 as a colorless solid (2.4 g, 99%) . To a solution of 57 (1.45 g, 2.08 mmol) in dry DMF (5 mL), was added a 30 seconds-premixed solution of HATU (949 mg, 2.50 mmol), Fmoc-Glu(OtBu)-OH (1.06 g, 2.50 mmol) and DIPEA (435 µL, 2.50 mmol) in dry DMF (5 mL). Reaction mixture was stirred at rt for 30 min. Reaction mixture was diluted with EtOAc and washed with NaHCO3 sat. aq. solution (x3), 10% citric acid solution (x3), water (x1), 5% LiCl solution (x2) and brine. Organic phase was then dried with Na2SO4, filtered and concentrated. Crude was dissolved in a minimal amount of CH2Cl2 and precipitated in pentane (x3). Crude was then purified by flash column chromatography (BGB® Scorpius 40 g SiO2 col., 40 mL/min, linear gradient 0 -8% MeOH in CH2Cl2) to yield 58 as a colorless solid (2.21 g, 96%) . Rf (CH2Cl2 + 10% MeOH): 0.5; Compound 59 was prepared following the general procedure of Fmoc deprotection, starting from 58 (2.20 g, 1.99 mmol) in 10 mL of 2 M dimethylamine in THF, yielding 59 as a colorless solid (1.59 g, 90%). Compound 60. To a solution of 59 (790 mg, 0.896 mmol) in dry DMF (4 mL), was added a 30 seconds-premixed solution of HATU (409 mg, 1.08 mmol), Fmoc-Lys(Boc)-OH (504 mg, 1.08 mmol) and DIPEA (187 µL, 1.08 mmol) in dry DMF (4 mL). Reaction mixture was stirred at rt for 30 min. Reaction mixture was diluted with EtOAc and washed with NaHCO3 sat. aq. solution (x3), 10% citric acid solution (x3), water (x1), 5% LiCl solution (x2) and brine. Organic phase was then dried with Na2SO4, filtered and concentrated. Crude was dissolved in a minimal amount of CH2Cl2 and precipitated in pentane (x3). Crude was then purified by flash column chromatography (BGB® Scorpius 40 g SiO2 col., 40 mL/min, linear gradient 0 -8% MeOH in CH2Cl2) to yield 60 as a colorless solid (1.03 g, 86%). Rf (CH2Cl2 + 19% MeOH): 0.5; MeOH) (s, 9H), 1.43 (s, 9H), 1.42 (s, 27H); 13 C NMR (101 MHz, CD3OD): 175.6 (C), 174.6 (C), 174.1 (C), 173.8 (C), 173.7 (2xC), 173.7 (C), 159.0 (C), 158.6 (C), 158.4 (2xC), 145.3 (C), 145.2 (C), 142.6 (C), 142.6 (C), 128.9 (2xCH), 128.2 (2xCH), 126.3 (2xCH) , 121.0 (2xCH), 81.9 (2xC), 81.9 (C), 80.6 (C), 79.9 (2xC), 72.3 (CH), 68.2 (CH2), 57.1 (CH), 55.3 (CH), 54.5 (2xCH), 54.3 (CH), 48.4 (CH), 41.2 (CH2), 41.2 (CH2), 41.1 (CH2), 32.7 (3xCH2), 32.5 (2xCH2), 32.2 (CH2), 30.6 (CH2), 30.5 (CH2), 30.4 (CH2), 29.6 (CH2), 28.9 (9xCH3), 28.4 (6xCH3), 27.8 (2xCH2), 24.2 (3xCH2). Compound 61 was prepared following the general procedure of Fmoc deprotection, starting from 60 (974 mg, 0.731 mmol) in 8 mL of 2 M dimethylamine in THF, yielding 61 as a colorless solid (778 mg, 98%). Compound 62. To a solution of 61 (740 mg, 0.666 mmol) in dry DMF (4 mL), was added a 30 seconds-premixed solution of HATU (304 mg, 0.800 mmol), Fmoc-Glu(OtBu)-OH (340 mg, 0.800 mmol) and DIPEA (139 µL, 0.800 mmol) in dry DMF (4 mL). Reaction mixture was stirred at rt for 30 min. Reaction mixture was diluted with EtOAc and washed with NaHCO3 sat. aq. solution (x3), 10% citric acid solution (x3), water (x1), 5% LiCl solution (x2) and brine. Organic phase was then dried with Na2SO4, filtered and concentrated. Crude was dissolved in a minimal amount of CH2Cl2 and precipitated in pentane (x3). Crude was then purified by flash column chromatography (BGB® Scorpius 40 g SiO2 col., 40 mL/min, linear gradient 0 -8% MeOH in CH2Cl2) to yield 62 as a colorless solid (941 mg, 93%). Rf (CH2Cl2 + 10% MeOH): 0.5; 126.2 (CH) , 121.0 (2xCH), 81.9 (C), 81.9 (C), 81.9 (C), 80.6 (C), 79.9 (3xC), 72.3 (CH), 68.2 (CH2), 56.4 (CH), 55.4 (CH), 54.8 (CH), 54.6 (2xCH), 54.5 (CH), 48.5 (CH), 41.3 (3xCH2), 32.9 (CH2), 32.8 (3xCH2), 32.6 (CH2), 32.3 (CH2), 30.5 (2xCH2), 30.5 (CH2), 29.6 (CH2), 28.9 (6xCH3), 28.9 (3xCH3), 28.5 (6xCH3), 28.5 (3xCH3), 28.1 (CH2), 27.8 (2xCH2), 24.3 (CH2), 24.2 (2xCH2). Compound 63 was prepared following the general procedure of Fmoc deprotection, starting from 62 (870 mg, 0.573 mmol) in 8 mL of 2 M dimethylamine in THF, yielding 63 as a colorless solid (725 mg, 98%). Compound 64. To a solution of 63 (670 mg, 0.517 mmol) in dry DMF (4 mL), was added a 30 seconds-premixed solution of HATU (236 mg, 0.620 mmol), 35 (201 mg, 0.620 mmol) and DIPEA (108 µL, 0.620 mmol) in dry DMF (4 mL). Reaction mixture was stirred at rt for 30 min. Reaction mixture was diluted with EtOAc and washed with NaHCO3 sat. aq. solution (x3), 10% citric acid solution (x3), water (x1), 5% LiCl solution (x2) and brine. Organic phase was then dried with Na2SO4, filtered and concentrated. Crude was dissolved in a minimal amount of CH2Cl2 and precipitated in pentane (x3). Crude was then purified by flash column chromatography (BGB® Scorpius 25 g SiO2 col., 40 mL/min, linear gradient 0 -8% Compound 65. To a solution of 64 (577 mg, 0.360 mmol) in THF/H2O 2/1 (9 mL), 36 (135 mg, 0.432 mmol), CuSO4·5H2O (90 mg, 0.36 mmol), sodium ascorbate (143 mg, 0.721 mmol) and TBTA (19 mg, 0.0036 mmol) were added and the reaction mixture was stirred at rt for 1 h. Solvent was removed in vacuo, H2O and CH2Cl2 were added, phases were separated, and aqueous phase was extracted by CH2Cl2 (x3). Organic phases were collected together, washed with brine (x1), dried over Na2SO4, filtered and concentrated. Crude was purified by flash column chromatography (BGB® Scorpius 25g, 25 mL/min, linear gradient 0 -10% MeOH in CH2Cl2) to yield 65 as a colorless solid (595 mg, 86%). Rf (CH2Cl2 + 10% MeOH): ( and TBTA (7 mg, 0.01 mmol) were added and the reaction mixture was stirred at rt for 1 h. ( NaHCO3 sat. aq. solution (x3), 10% citric acid solution (x3), water (x1), 5% LiCl solution (x2) and brine. Organic phase was then dried with Na2SO4, filtered and concentrated. Crude was dissolved in a minimal amount of CH2Cl2 and precipitated in pentane (x3 and brine. Organic phase was then dried with Na2SO4, filtered and concentrated. Crude was dissolved in a minimal amount of CH2Cl2 and precipitated in pentane (x3). Crude was then PBS, 1 mL), the different peptides 4-11 (6 μL, 10 mM in DMSO, 3 equivalents) were added and the mixture was shaken for 10 min at rt. Then, the complexes 1, 15-26 were concentrated and washed with PBS (3 x 0.5 mL) using Amicon® Ultra 0.5 mL centrifugal filters (cut off: 30 kDa, 10 min, 4.0 krpm). The material was recovered from the centrifugal filter and diluted again with PBS to the required concentration (i.e., 200 μM, 100 μL). Complex 23 was similarly prepared using 4 µL of peptide 13 (10 mM in DMSO, 2 equivalents). Complex 24 was similarly prepared using 2 µL each of peptides 12 and 13 (10 mM in DMSO, 1 equivalent each). Complex 25 was similarly prepared using 4 µL of peptide 14 (10 mM in DMSO, 2 equivalents). Complex 26 was similarly prepared using 2 µL each of peptides 13 and 14 (10 mM in DMSO, 1 equivalent each). The cells were originally designed by the Chenoweth lab as described in ref. S10. They were cultured using the described procedure in ref. S4. Figure S2 . Duplicates were performed for each condition. As in ref. S11, for each cell, the DAPI and GFP channel images were used for the segmentation of the nuclei and whole cell body, respectively. Three successive filters have then been used for the cell selection process: 1) Cells positively expressing GFP (GFP channel with minimum intensity threshold). 2) The shape of the nucleus, to eliminate dead or dividing cell (maximum roundness of 0.7, with roundness = height / length). Cells partially outside of the picture were also removed. 3) The size of the nucleus, an additional filter for dividing and dead cells (minimum area of 130 µm 2 ). The mitochondrial mask was then applied to extract the integrated intensity values (sum of the intensities of the pixels included in the mask) in the red channel image, from the labeling with compound HRO 2 ( Figure S3 ). Duplicates were performed for each condition. The resulting dependence of the relative intensity values (Irel) to the concentration of complexes 1, 15-26 (c) was plotted and fitted with equation (S1) to retrieve the half-maximal penetration concentration (CP50) value (n is the Hill coefficient). Figure S4 . Duplicates were performed for each condition. For each spheroid, the TL and green channel images were used for the segmentation of the object. A gaussian filter was applied to blur the image and allow the creation of the spheroid body mask ( Figure S5 ). Green channel recording the GFP signal in the mitochondria (left), applied Gaussian filter (middle) to generate the spheroid mask in white (right). Images are 2D projections of all planes. Scale bar: 100 μm. Spheroid mask was applied to extract the average intensity values (average of the intensities of the pixels included in the mask) in the red channel image, from the labeling with compound HRO 2 ( Figure S5 ). and light blue channel recording the signal from QDs 28 (right). Cross-sectional images were taken at 80 μm from the bottom. Scale bar: 100 μm. As in section 3.3.2., for each spheroid, the TL and green channel images were used for the segmentation of the object using a gaussian filter. To remove the bright fluorescent QDs aggregates, a "find blob" module was applied ( Figure S7 ), to generate a modified spheroid body mask which was used to extract the average intensity values (average of the intensities of the pixels included in the mask) in the QDs channel image ( Figure S7 ). Spheroid body mask (left), detection of bright aggregates with a "find blob" module (middle) and applied final spheroid body mask (right). Scale bar: 100 μm. Average fluorescent intensity values per spheroid (I) were calculated by subtracting average background intensity (control spheroid without addition of QDs) to the average intensity of the QDs-treated spheroids. Average intensities IT for each condition were normalized against that obtained with spheroids treated with QD complex 27 (I0) using Equation (S3): Results from quantification are shown in Figure S8 . Relative average intensities with standard deviation extracted from the QD channel, corresponding to the spheroids treated with 27 and 28, respectively. To a freshly prepared solution of WT streptavidin 3 (200 μM in PBS, 1 mL), 4 (2 μL, 10 mM in DMSO, 2 equivalents) and SupraFlipper 29 (10 μL, 1 mM in DMSO, 1 equivalents) were added and the mixture was shaken for 10 min at rt. Aggregates were spun down for 1 min. Control complex 34 was prepared similarly, without the addition of 4 ( Figure S9 ). As in section 3.3.2., for each spheroid, the TL and green channel images were used for the segmentation of the object using a gaussian filter. In addition, several filters were added to generate a layer quantification. Briefly, the spheroid body mask was shrunk to create layers starting from center to the extremities ( Figure S10 ), to generate a modified spheroid body mask. Layer 1 in white ( Figure S10 ) was used to extract the average intensity values (average of the S85 intensities of the pixels included in the layer) in the GFP-TxRed channel image to report on maximal penetration of the complex ( Figure S10 ). Red channel recording the SupraFipper signal in the spheroid after addition of biotin for 2 h (left), Layer analysis applied to the red channel with layer 1 (white), layer 2 (yellow), layer 3 (blue) and layer 4 (pink) masks (right). Cross-sectional CSDM images were taken at 80 μm from the bottom. Scale bar: 100 μm. Delivery and release were performed as in section 4.1.2. The average intensity values for each condition were obtained using analysis protocol in section 4.1.3. The resulting average fluorescent intensity values per spheroid (I) were normalized compared to the intensity of the spheroids treated with complex 34 before addition of biotin (I0), using Equation (S4), to give IT: Results from the experiments are reported in Figure S11 . Finally, a solution of NaCl (5 M, 1.1 mL) was added, to reach a final concentration of NaCl of 1 M. After 10 min, images in both channels were again acquired. Organic phase was then dried with Na2SO4, filtered and concentrated. Crude was dissolved in a minimal amount of CH2Cl2 and precipitated in pentane (x3) MeOH in CH2Cl2) to yield 123 as a colorless solid (572 mg, 87%). Rf (CH2Cl2 + 10% MeOH IR (neat): 3296 (m), 2935 (m) 1626 (s), 1518 (s), 1452 (m), 1365 (m), 1248 (s), 1168 (s) m, 18H), 1.37 -1.15 (m, 28H), 1.33 (s, 54H 2 (CH), 53.1 (CH) IR (neat): 3271 (m), 2935 (m), 1690 (s) 1524 (s), 1454 (m), 1248 (s), 1169 (s), 1055 (s), 1014 (s) m, 4H), 3.17 (t, 3 JH-H = 5.7 Hz, 2H) m, 30H), 1.32 (s, 54H 77.8 (C), 77.8 (2xC), 77.7 (3xC) CH) 53.3 (CH), 53.0 (CH) 3 (CH2), 31.1 (CH2), 31.1 (CH2), 30.9 (CH2), 30.6 (2xCH2) Solvent was removed in vacuo, crude was dissolved in small amount of MeOH and was precipitated in Et2O (x3) to yield 14 as a colorless TFA salt (166 mg, 91%). 1 H NMR (500 MHz, DMSO-d6): 8.41 (br s, NH) 3 (CH2), 31.2 (CH2), 31.1 (CH2), 30.8 (CH2), 30.6 (2xCH2) HRMS (ESI, +ve) calcd for C65H121ClN20O12S 67 (d, 3 JH-H = 7.3 Hz, NH), 6.42 (s, NH), 6.36 (s, NH) 7 (2xCH2), 30.5 (CH2) BGB® Scorpius 25 g SiO2 col., 40 mL/min, linear gradient 0 -8% MeOH in CH2Cl2) to yield 129 as a colorless solid (1.02 g, 90%) IR (neat): 3292 (m), 2977 (m), 1728 (s), 1626 (s), 1520 (s), 1452 (m), 1366 (m), 1253 (m), 1253 (m), 1148 (s) MHz, CD3OD): 7.81 (d, 3 JH-H = 7.5 Hz, 2H), 7.69 (d, 3 JH-H = 7.5 Hz, 2H), 7.40 (t, 3 JH-H = 7.5 Hz, 2H), 7.32 (t, 3 JH-H = 7.5 Hz, 2H), 4.52 (dd, 2 JH-H = 10.5, 3 JH-H = 6.9 Hz, 1H) 2xC), 127.6 (2xCH), 127.0 (2xCH), 125.3 (2xCH 80.8 (C), 79.7 (2xC), 79.6 (C), 79.6 (2xC), 79.6 (C), 73.1 (CH), 65.7 (CH2) Compound 130 was prepared following the general procedure of Fmoc deprotection, starting from 129 (504 mg, 0.363 mmol) in 9 mL of 2 M dimethylamine in THF To a solution of 130 (349 mg, 0.299 mmol) in dry DMF (1 mL), was added a 30 seconds-premixed solution of HATU (137 mg, 0.359 mmol) DIPEA (63 µL, 0.359 mmol) in dry DMF (1 mL). Reaction mixture was stirred at rt for 30 min. Reaction mixture was diluted with EtOAc and washed with NaHCO3 sat. aq. solution (x3), 10% citric acid solution (x3), water (x1), 5% LiCl solution (x2) and brine Organic phase was then dried with Na2SO4, filtered and concentrated. Crude was dissolved in a minimal amount of CH2Cl2 and precipitated in pentane (x3) MeOH in CH2Cl2) to yield 131 as a colorless solid (340 mg, 77%). Rf (CH2Cl2 + 10% MeOH IR (neat): 3283 (m), 2977 (m) 1624 (s), 1522 (s), 1450 (m), 1366 (m), 1254 (m), 1148 (s) 49 (t, 3 JH-H = 6.6 Hz, 2H), 3.46 -3.34 (m, 2H), 2.87 -2.77 (m, 1H), 2.59 -2.48 (m, 3H), 2.51 (t, 4 JH-H = 2.5 Hz, 1H), 2.47 -2.30 (m, 12H), 2.23 -2.10 (m, 6H), 2.08 -1.92 (m, 6H), 1.83 -1.73 (m, 2H), 1.65 -1.56 (m, 2H), 1.52 -1.34 (m, 4H), 1.45 (s, 9H), 1.44 (s, 36H), 1.44 (s, 9H) 30.5 (CH2), 29.1 (CH2), 28.0 (CH2), 27.7 (18xCH3), 27.2 (CH2), 27.1 (CH2) To a solution of 131 (232 mg, 0.158 mmol) in THF/H2O 2/1 (5 mL), 36 (59 mg, 0.19 mmol), CuSO4·5H2O (39 mg, 0.16 mmol), sodium ascorbate (62 mg 16 µmol) were added and the reaction mixture was stirred at rt for 1 h. Solvent was removed in vacuo, H2O and CH2Cl2 were added, phases were separated, and aqueous phase was extracted by CH2Cl2 (x3) CH2Cl2) to yield 132 as a colorless solid (235 mg, 83%) IR (neat): 3296 (m), 2934 (m), 1726 (s) 1366 (s), 1150 (s), 845 (m), 563 (m) Hz, 2H), 3.49 (t, 3 JH-H = 6.6 Hz, 2H) Hz, 1H), 2.61 -2.31 (m, 15H), 2.25 -1.96 (m, 14H), 1.82 -1.68 (m, 3H), 1.67 -1.54 (m, 5H), 1.52 -1 172.5 (C), 172.2 (C) 3 (2xCH2), 31.2 (CH2), 31.2 (2xCH2), 30.8 (CH2) 29.1 (CH2), 28.1 (CH2), 28.0 (CH2), 27.7 (18xCH3), 27.2 (CH2), 27.0 (CH2) mL) was stirred at rt for 30 min. Solvent was removed in vacuo, crude was dissolved in small amount of MeOH and was precipitated in Et2O (x3) to yield 13 as a colorless solid DMSO-d6): 12.07 (br s, 6H) 82 (dd, 2 JH-H = 12.4, 3 JH-H = 5.1 Hz, 1H), 2.57 (d, 2 JH-H = 12.4 Hz, 1H) CH2), 69.6 (CH2), 69.4 (CH2), 69.1 (CH2), 61.0 (CH), 59.2 (CH Scheme S10 a) 4-14, PBS, rt, 10 min. Complexes Qdot TM 605 streptavidin conjugate 27 (1 μM in PBS, 3 μL), 5 (24 μL, 10 μM in PBS As in section 3.3.1., HGM cells were seeded at 5 × 10 3 cells/mL in FluoroBrite DMEM After the spheroids were formed, the medium was exchanged to Leibovitz's (6 × 200 μL/well) using a Biotek MultiFlo TM FX plate washer QDs complexes 27 and 28 in PBS were added to the μ-Plate containing the spheroids (15 μL/well, 10x final concentration in PBS) to reach a final volume of 150 μL/well (final concentration = 10 nM), except for the control wells After this, spheroids were washed and imaged with a z-stack of 19 images/well (10 μm per step) at 10x, using three channels: Transmitted light, green (excitation filter: 475/34 nm, emission filter: 536/40 nm, exposure time: 200 ms) and GFP-TxRed 200 ms), as shown in Figure S6. During imaging, samples were kept at References S1 S6 a) The original data can be